ArticleNature protocols2013
CRISPR interference (CRISPRi) for sequence-specific control of gene expression.
Article in Nature protocols, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 663 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
663 citing papers in PubMed, 1,237 citations in OpenAlex.
- CRISPR/Cas Systems: Biological Basis and Genome Editing Applications.Methods in molecular biology (Clifton, N.J.) · 2027Review
- Genetic and Epigenetic Manipulation Using CRISPR Techniques in Ewing Sarcoma.Methods in molecular biology (Clifton, N.J.) · 2027Article
- Precise probiotic therapy: Advances, bottlenecks, and the road to microbiome-informed nutrition.Gut microbes · 2026Review
- Utilization of the CRISPR-Cas system for investigating tuberculosis drug resistance.Molecular biology reports · 2026Review
- Next-Generation Therapies for Genetic Diseases: The Synergy of CRISPR and Gene Therapy.Biochemical genetics · 2026Review
- Structural and genetic dissection of RNA-guided gene repression by TnpB-derived transcription factors.bioRxiv : the preprint server for biology · 2026Article
- Development of an investigational epigenetic silencer therapy to transcriptionally inactivate viral DNA in chronic hepatitis B.Nature biomedical engineering · 2026Article
- The application of the CRISPR-Cas system in Pseudomonas aeruginosa infections.Molecular biology reports · 2026Review
- A genetically encoded redox bottleneck constrains human developmental rate.bioRxiv : the preprint server for biology · 2026Article
- Identification of a putative RocS homolog through phenotypic profiling of uncharacterized essential genes inbioRxiv : the preprint server for biology · 2026Article
- Cap-Independent Translation Regulation of VEGF Using CRISPR-dCas13d.bioRxiv : the preprint server for biology · 2026Article
- High-Content CRISPR Screening: Methods and Applications.MedComm · 2026Review
- A dual-platform toolkit for transient gene expression and genome editing in rubber dandelion (aBIOTECH · 2026Article
- Article
- Constructing an Adenine Base Editor inMicroorganisms · 2026Article
- Lactic Acid Bacteria-Derived γ-Aminobutyric Acid: From Targeted Screening and Biosynthesis to Functional Food Applications and Health Benefits.Foods (Basel, Switzerland) · 2026Review
- Review
- A cross-strain CRISPRi sgRNA library forMicrobiology resource announcements · 2026Article
- Article
- A portable Cas6f-based system for multiplex translational repression in bacteria.Nature communications · 2026Article
603 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
Abstract
Sequence-specific control of gene expression on a genome-wide scale is an important approach for understanding gene functions and for engineering genetic regulatory systems. We have recently described an RNA-based method, CRISPR interference (CRISPRi), for targeted silencing of transcription in bacteria and human cells. The CRISPRi system is derived from the Streptococcus pyogenes CRISPR (clustered regularly interspaced palindromic repeats) pathway, requiring only the coexpression of a catalytically inactive Cas9 protein and a customizable single guide RNA (sgRNA). The Cas9-sgRNA complex binds to DNA elements complementary to the sgRNA and causes a steric block that halts transcript elongation by RNA polymerase, resulting in the repression of the target gene. Here we provide a protocol for the design, construction and expression of customized sgRNAs for transcriptional repression of any gene of interest. We also provide details for testing the repression activity of CRISPRi using quantitative fluorescence assays and native elongating transcript sequencing. CRISPRi provides a simplified approach for rapid gene repression within 1-2 weeks. The method can also be adapted for high-throughput interrogation of genome-wide gene functions and genetic interactions, thus providing a complementary approach to RNA interference, which can be used in a wider variety of organisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.